Cargando…
Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications
BACKGROUND/AIMS: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. METHODS: We reviewed the medical records of MM patients whose age was 40 y...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511945/ https://www.ncbi.nlm.nih.gov/pubmed/28651310 http://dx.doi.org/10.3904/kjim.2016.256 |
_version_ | 1783250423675617280 |
---|---|
author | Shin, Junghoon Koh, Youngil Youk, Jeonghwan Kim, Miso Kim, Byung Soo Choi, Chul Won Sung, Hwa Jung Park, Yong Yoon, Sung-Soo Kim, Inho |
author_facet | Shin, Junghoon Koh, Youngil Youk, Jeonghwan Kim, Miso Kim, Byung Soo Choi, Chul Won Sung, Hwa Jung Park, Yong Yoon, Sung-Soo Kim, Inho |
author_sort | Shin, Junghoon |
collection | PubMed |
description | BACKGROUND/AIMS: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. METHODS: We reviewed the medical records of MM patients whose age was 40 years or younger at diagnosis. RESULTS: A total of 32 patients were analyzed (male to female ratio 19:13, median age 37 years). According to International Staging System, 29%, 48%, and 16% were in stage I, II, and III, respectively. Light chain myeloma accounted for 30%. Clinically significant anemia, hypercalcemia, azotemia, and hypoalbuminemia were present in 29%, 28%, 13%, and 28%, respectively. Three or more lytic bone lesions were detected in 45% of the patients, whereas 13% had no lytic bone lesions. Regarding treatment, 79% of patients received autologous hematopoietic stem cell transplantation. After a median follow-up duration of 64 months, the 1-, 3-, and 5-year overall survival (OS) rates were 84%, 62%, and 54%, respectively. The median OS was 61 months for the entire cohort. CONCLUSIONS: In our study, MM patients aged 40 years or younger at diagnosis showed no superior survival compared to those of the moderately elderly patients based on historical data. |
format | Online Article Text |
id | pubmed-5511945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-55119452017-07-17 Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications Shin, Junghoon Koh, Youngil Youk, Jeonghwan Kim, Miso Kim, Byung Soo Choi, Chul Won Sung, Hwa Jung Park, Yong Yoon, Sung-Soo Kim, Inho Korean J Intern Med Original Article BACKGROUND/AIMS: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. METHODS: We reviewed the medical records of MM patients whose age was 40 years or younger at diagnosis. RESULTS: A total of 32 patients were analyzed (male to female ratio 19:13, median age 37 years). According to International Staging System, 29%, 48%, and 16% were in stage I, II, and III, respectively. Light chain myeloma accounted for 30%. Clinically significant anemia, hypercalcemia, azotemia, and hypoalbuminemia were present in 29%, 28%, 13%, and 28%, respectively. Three or more lytic bone lesions were detected in 45% of the patients, whereas 13% had no lytic bone lesions. Regarding treatment, 79% of patients received autologous hematopoietic stem cell transplantation. After a median follow-up duration of 64 months, the 1-, 3-, and 5-year overall survival (OS) rates were 84%, 62%, and 54%, respectively. The median OS was 61 months for the entire cohort. CONCLUSIONS: In our study, MM patients aged 40 years or younger at diagnosis showed no superior survival compared to those of the moderately elderly patients based on historical data. The Korean Association of Internal Medicine 2017-07 2017-06-26 /pmc/articles/PMC5511945/ /pubmed/28651310 http://dx.doi.org/10.3904/kjim.2016.256 Text en Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Shin, Junghoon Koh, Youngil Youk, Jeonghwan Kim, Miso Kim, Byung Soo Choi, Chul Won Sung, Hwa Jung Park, Yong Yoon, Sung-Soo Kim, Inho Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications |
title | Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications |
title_full | Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications |
title_fullStr | Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications |
title_full_unstemmed | Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications |
title_short | Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications |
title_sort | clinicopathological characteristics of extremely young korean multiple myeloma patients: therapeutic implications |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511945/ https://www.ncbi.nlm.nih.gov/pubmed/28651310 http://dx.doi.org/10.3904/kjim.2016.256 |
work_keys_str_mv | AT shinjunghoon clinicopathologicalcharacteristicsofextremelyyoungkoreanmultiplemyelomapatientstherapeuticimplications AT kohyoungil clinicopathologicalcharacteristicsofextremelyyoungkoreanmultiplemyelomapatientstherapeuticimplications AT youkjeonghwan clinicopathologicalcharacteristicsofextremelyyoungkoreanmultiplemyelomapatientstherapeuticimplications AT kimmiso clinicopathologicalcharacteristicsofextremelyyoungkoreanmultiplemyelomapatientstherapeuticimplications AT kimbyungsoo clinicopathologicalcharacteristicsofextremelyyoungkoreanmultiplemyelomapatientstherapeuticimplications AT choichulwon clinicopathologicalcharacteristicsofextremelyyoungkoreanmultiplemyelomapatientstherapeuticimplications AT sunghwajung clinicopathologicalcharacteristicsofextremelyyoungkoreanmultiplemyelomapatientstherapeuticimplications AT parkyong clinicopathologicalcharacteristicsofextremelyyoungkoreanmultiplemyelomapatientstherapeuticimplications AT yoonsungsoo clinicopathologicalcharacteristicsofextremelyyoungkoreanmultiplemyelomapatientstherapeuticimplications AT kiminho clinicopathologicalcharacteristicsofextremelyyoungkoreanmultiplemyelomapatientstherapeuticimplications |